T-cell prolymphocytic leukemia medical therapy

T-cell prolymphocytic leukemia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating T-cell prolymphocytic leukemia historical perspective from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
T-cell prolymphocytic leukemia medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of T-cell prolymphocytic leukemia medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on T-cell prolymphocytic leukemia medical therapy
CDC on T-cell prolymphocytic leukemia medical therapy
T-cell prolymphocytic leukemia medical therapy in the news
Blogs on T-cell prolymphocytic leukemia medical therapy
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for T-cell prolymphocytic leukemia medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Qurrat-ul-ain Abid, M.D.[2], Maria Fernanda Villarreal, M.D. [3] Carlos A Lopez, M.D. [4]

Overview

T-cell prolymphocytic leukemia responds better when combinations of chemotherapy drugs are used. Monoclonal antibodies are a type of biological therapy that has been effective in treating certain types of leukemias. Splenectomy and external beam radiation therapy to the spleen may be used in some people with Prolymphocytic leukemia.

Medical Therapy

• The mainstay of therapy for T-cell prolymphocytic leukemia, include:

• Alemtuzumab (anti-CD52)

• T-cell prolymphocytic leukemia is often resistant to therapy.

Chemotherapy

T-cell prolymphocytic leukemia responds better when combinations of chemotherapy drugs are used. Some combinations that may be used are:

• CVP – Cyclophosphamide, vincristine and prednisone.

• CHOP – Cyclophosphamide, doxorubicin, vincristine and prednisone.

Other chemotherapy drugs (purine analogues) are often used to treat T-cell prolymphocytic leukemia are:

• Fludarabine
• Cladribine
• Pentostatin

Biological therapy

Monoclonal antibodies are a type of biological therapy that has been effective in treating certain types of leukemias. These drugs may be used alone or in combination with chemotherapy to treat prolymphocytic leukemia.

• Alemtuzumab seems to be particularly effective in treating T-cell prolymphocytic leukemia. It may be used in people whose lymphoma is no longer responding to chemotherapy drugs like fludarabine.

Splenectomy or radiation therapy to the spleen

Splenectomy and external beam radiation therapy to the spleen may be used in some people with Prolymphocytic leukemia.